Abstract:Background: β-adrenergic receptor (β-AR) overactivation is a major pathological cue associated with cardiac injury and diseases. AMPK (AMP-activated protein kinase), a conserved energy sensor, regulates energy metabolism and is cardioprotective. However, whether AMPK exerts cardioprotective effects via regulating the signaling pathway downstream of β-AR remains unclear. Methods: Using immunoprecipitation, mass spectrometry, site-specific mutation, in vitro kinase assay, and in vivo animal studies, we determined whether AMPK phosphorylates β-arrestin-1 at serine (Ser) 330. Wild-type mice and mice with site-specific mutagenesis (S330A knock-in [KI]/S330D KI) were subcutaneously injected with the β-AR agonist isoproterenol (5 mg/kg) to evaluate the causality between β-adrenergic insult and β-arrestin-1 Ser330 phosphorylation. Cardiac transcriptomics was used to identify changes in gene expression from β-arrestin-1-S330A/S330D mutation and β-adrenergic insult. Results: Metformin could decrease cAMP/PKA (protein kinase A) signaling induced by isoproterenol. AMPK bound to β-arrestin-1 and phosphorylated Ser330 with the highest phosphorylated mass spectrometry score. AMPK activation promoted β-arrestin-1 Ser330 phosphorylation in vitro and in vivo. Neonatal mouse cardiomyocytes overexpressing β-arrestin-1-S330D (active form) inhibited the β-AR/cAMP/PKA axis by increasing PDE (phosphodiesterase) 4 expression and activity. Cardiac transcriptomics revealed that the differentially expressed genes between isoproterenol-treated S330A KI and S330D KI mice were mainly involved in immune processes and inflammatory response. β-arrestin-1 Ser330 phosphorylation inhibited isoproterenol-induced reactive oxygen species production and NLRP3 (NOD-like receptor protein 3) inflammasome activation in neonatal mouse cardiomyocytes. In S330D KI mice, the β-AR-activated cAMP/PKA pathways were attenuated, leading to repressed inflammasome activation, reduced expression of proinflammatory cytokines, and mitigated macrophage infiltration. Compared with S330A KI mice, S330D KI mice showed diminished cardiac fibrosis and improved cardiac function upon isoproterenol exposure. However, the cardiac protection exerted by AMPK was abolished in S330A KI mice. Conclusions: AMPK phosphorylation of β-arrestin-1 Ser330 potentiated PDE4 expression and activity, thereby inhibiting β-AR/cAMP/PKA activation. Subsequently, β-arrestin-1 Ser330 phosphorylation blocks β-AR-induced cardiac inflammasome activation and remodeling.

PKI-GFP Prevents Cardiac Dysfunction and Myocyte Death Induced by ISO

Cardiotoxic and Cardioprotective Features of Chronic Β-Adrenergic Signaling

Advanced Glycation End Products Facilitate Proliferation and Reduce Early Apoptosis of Cardiac Microvascular Endothelial Cell Via PKCβ Signaling Pathway: Insight from Diabetic Cardiomyopathy

Abstract 19829: PKIalpha Modulates Adrenergic Signaling in Cardiac Physiology and Pathophysiology

Pkialpha Protects Hearts From Beta-adrenergic Overstimulation

Abstract 122: Pkialpha Protects Hearts From Beta-adrenergic Overstimulation

Cardiomyocyte PKA Ablation Enhances Basal Contractility While Eliminates Cardiac β-Adrenergic Response Without Adverse Effects on the Heart.

Abstract 495: The Loss Of Pka Activity And Activation In Cardiomyocytes Does Not Induce Cardiac Abnormalities

Abstract 18932: Pka is a Master Regulator of Cardiac Hypertrophy Induced by Pressure Overload

Cardiomyocyte PKA ablation eliminates cardiac β-adrenergic response without adverse effects on the heart

Abstract 72: Pka is A Master Regulator of Pathological Cardiac Hypertrophy

Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy

Abstract 17498: PKA is the Canonical Mediator of “Fight-or-flight” Response of the Heart

Protein Kinase C Activation in Cardiac Hypertrophy and Failure

PFKP inhibition protects against pathological cardiac hypertrophy by regulating protein synthesis

Linkage of Β1-Adrenergic Stimulation to Apoptotic Heart Cell Death Through Protein Kinase A–independent Activation of Ca2+/calmodulin Kinase II

Inhibition of Protein Kinase C Βii Isoform Ameliorates Methylglyoxal Advanced Glycation Endproduct-Induced Cardiomyocyte Contractile Dysfunction

Regulation of Na+-K+-ATPase leads to disturbances of isoproterenol-induced cardiac dysfunction via interference of Ca2+-dependent cardiac metabolism

AMPK Attenuation of β-Adrenergic Receptor-Induced Cardiac Injury via Phosphorylation of β-Arrestin-1-ser330

Reduction of Na/K-Atpase Potentiates Marinobufagenin-Induced Cardiac Dysfunction and Myocyte Apoptosis

Post-conditioning Protects Rat Cardiomyocytes Via PKCε-mediated Calcium-Sensing Receptors